Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
NCT00741780 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164
Last updated 2015-03-24
Summary
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
Conditions
- Multiple Myeloma
- Autologous Transplantation
Interventions
- DRUG
- DRUG
-
plerixafor
- DRUG
-
granulocyte colony-stimulating factor (G-CSF)
Sponsors & Collaborators
-
Genzyme, a Sanofi Company
lead INDUSTRY
Principal Investigators
-
Medical Monitor · Genzyme, a Sanofi Company
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-06-30
- Primary Completion
- 2011-07-31
- Completion
- 2011-07-31
More Related Trials
-
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
NCT00998049 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00903968 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Non-interventional Study on Salvage Auto in Relapsed Myeloma
NCT02439476 ·Status: COMPLETED
-
Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma
NCT02861287 ·Status: COMPLETED
-
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
NCT01753453 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
NCT01695590 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
NCT02181413 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
NCT02312258 ·Status: COMPLETED ·Phase: PHASE3
-
PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma
NCT01220375 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
NCT02474563 ·Status: COMPLETED
-
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
NCT00434161 ·Status: COMPLETED ·Phase: PHASE3
-
Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients
NCT03406091 ·Status: COMPLETED
-
Quantitating the Impact of Plerixafor
NCT02522572 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
NCT01301963 ·Status: TERMINATED ·Phase: PHASE3
-
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
NCT04552743 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
NCT00259740 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
NCT01037517 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
NCT00036140 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
NCT02997813 ·Status: COMPLETED
-
Two Cycles of PAD Combination by AHCT in MM
NCT01370434 ·Status: COMPLETED ·Phase: PHASE2
-
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
NCT03000634 ·Status: WITHDRAWN ·Phase: PHASE2
-
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508 ·Status: RECRUITING ·Phase: PHASE3
-
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
NCT04065308 ·Status: UNKNOWN ·Phase: PHASE2